Latest News and Press Releases
Want to stay updated on the latest news?
-
Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate CancerWebinar at 11AM ET on Friday, May 12. BOCA RATON, Fla., May 08, 2023 (GLOBE...
-
Boca Raton, Florida, Jan. 25, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
-
Company Dosed First Phase 2 Mild Alzheimer’s Disease Patient with Xpro1595; Presented Data from Ongoing INKmune™ Studies Suggesting Increased NK Cell Treatment Effective Against Solid Malignancies ...
-
BOCA RATON, Florida., Feb. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
-
Boca Raton, Florida, Jan. 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness...
-
Data suggests in triple negative breast cancer that MUC4 predicts survival and resistance to immunotherapy and that INB03 reverses resistance by decreasing immunosuppression in the TME Boca...
-
Boca Raton, FL., July 14, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that harness...
-
Boca Raton, FL, July 12, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
-
LA JOLLA, Calif, March 08, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a...
-
100 patient blinded, randomized, biomarker-directed Phase 2 study will use neuroimaging technology to study the complex biology of treatment resistant disease Study supports INmune...